New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|June 13, 2014
Bevacizumab and Improvement of PFS in Ovarian Cancer
Author(s)Sean C. Dowdy, MD
Sean C. Dowdy, MD, professor, chair, Division of Gynecologic Surgery, co-leader, Women’s Cancer Program, Mayo Clinic, discusses bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.
Advertisement
Sean C. Dowdy, MD, professor, chair, Division of Gynecologic Surgery, co-leader, Women’s Cancer Program, Mayo Clinic, discusses bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.
Clinical Pearls:
- ICON7, a previous study, demonstrated that the addition of bevacizumab to carboplatin and paclitaxel improves progression-free survival (PFS), but not overall survival (OS) in first-line treatment of ovarian cancer
- The goal of this analysis was to determine if response to bevacizumab was associated with the molecular classification as described by The Cancer Genome Atlas (TCGA) project.
- The analysis identified four groups of tumors according to TCGA: differentiated, immunoreactive, mesenchymal and proliferative.
- The proliferative and mesenchymal groups had a better response to bevacizumab and showed an improvement in PFS compared to the two other molecular subtypes.
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
4
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
5